The market expects Sage Therapeutics, Inc. (SAGE) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely-known ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $0.55 per share a year ago. These ...

Sage Therapeutics SAGE reported a loss of $3.37 per share for the third quarter of 2023, wider than the year-ago quarter’s loss of $2.31. The reported loss included restructuring expenses of $33.6 ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus ...